Avantax Advisory Services Inc. Sells 17,660 Shares of Certara, Inc. (NASDAQ:CERT)

Avantax Advisory Services Inc. trimmed its stake in shares of Certara, Inc. (NASDAQ:CERT) by 34.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 33,857 shares of the company’s stock after selling 17,660 shares during the quarter. Avantax Advisory Services Inc.’s holdings in Certara were worth $361,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. HighTower Advisors LLC lifted its holdings in Certara by 647.2% in the fourth quarter. HighTower Advisors LLC now owns 146,539 shares of the company’s stock valued at $1,561,000 after buying an additional 126,927 shares during the period. Amundi boosted its position in Certara by 222.8% during the 4th quarter. Amundi now owns 62,167 shares of the company’s stock worth $685,000 after acquiring an additional 42,907 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of Certara by 188.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 20,797 shares of the company’s stock worth $221,000 after buying an additional 13,592 shares during the last quarter. Edgestream Partners L.P. raised its position in Certara by 140.3% during the fourth quarter. Edgestream Partners L.P. now owns 365,708 shares of the company’s stock worth $3,895,000 after acquiring an additional 213,549 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Certara during the 4th quarter worth approximately $3,628,000. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

CERT has been the subject of several recent research reports. Barclays boosted their price target on Certara from $12.00 to $13.00 and gave the company an “equal weight” rating in a research note on Friday, February 28th. William Blair reiterated a “market perform” rating on shares of Certara in a report on Thursday, February 27th. TD Cowen initiated coverage on shares of Certara in a research report on Thursday, February 27th. They set a “buy” rating and a $16.00 price objective for the company. Finally, Stephens reaffirmed an “overweight” rating and set a $17.00 price target on shares of Certara in a research note on Thursday, February 27th. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, Certara has a consensus rating of “Moderate Buy” and a consensus target price of $15.83.

Certara Stock Performance

Certara stock opened at $10.78 on Tuesday. The firm’s 50 day simple moving average is $12.54 and its 200 day simple moving average is $11.48. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. Certara, Inc. has a 1-year low of $9.41 and a 1-year high of $19.18. The firm has a market capitalization of $1.74 billion, a PE ratio of -53.90, a price-to-earnings-growth ratio of 9.29 and a beta of 1.60.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.